GILDHealthcare · Drug Manufacturers - GeneralThe 28 Wall Street analysts covering Gilead Sciences, Inc. hold a median 12-month price target of $165 — +4.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Gilead Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Issuance (50): The company has been issuing shares or taking on financing, diluting existing holders.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GILD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +4.8% from it.
Of the 20 most recent actions, 5 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Oct 2026 | Cantor Fitzgerald | Reiterates | Overweight | $155 |
| 8 Oct 2026 | RBC Capital | Maintains | Sector Perform | $123 → $126 |
| 7 Oct 2026 | JP Morgan | Maintains | Overweight | $160 → $170 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Overweight | $165 → $163 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $150 → $158 |
| 10 Sept 2026 | HSBC | Maintains | Buy | $155 → $175 |
| 10 Sept 2026 | HSBC | Maintains | Buy | — |
| 5 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 5 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $155 |
| 5 Aug 2026 | Needham | Reiterates | Buy | $170 |
| 5 Aug 2026 | Needham | Reiterates | Buy | — |
| 5 Aug 2026 | RBC Capital | Maintains | Sector Perform | — |
| 5 Aug 2026 | RBC Capital | Maintains | Sector Perform | $120 → $123 |
| 29 July 2026 | Barclays | Maintains | Equal-Weight | $155 → $145 |
| 29 July 2026 | Barclays | Maintains | Equal-Weight | — |
| 27 July 2026 | Morgan Stanley | Maintains | Overweight | $166 → $165 |
| 27 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 21 July 2026 | Leerink Partners | Downgrade | Market Perform | — |
| 21 July 2026 | Leerink Partners | Downgrade | Market Perform | $146 → $127 |
| 8 July 2026 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GILD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Oct 2026, Gilead Sciences, Inc. returned +36.3% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 40% of US stocks
Cheaper than 21% of US stocks
Cheaper than 6% of US stocks
Cheaper than 24% of US stocks
Higher than 52% of US stocks
Higher than 48% of US stocks
Higher than 90% of US stocks
Higher than 89% of US stocks
Higher than 19% of US stocks
Higher than 31% of US stocks
Higher than 96% of US stocks
Higher than 80% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Gilead Sciences, Inc. has a market value of $183.4B and an enterprise value of $207.8B.
Revenue in the twelve months to 30 June 2026: $30.5B. The latest quarter grew 10.2% year on year.
Net income over the same four quarters: −$3.2B, a −10.6% net margin.
Diluted earnings per share, trailing twelve months: $−2.67.
Free cash flow in the twelve months to 30 June 2026: $12.9B.
Gilead Sciences, Inc. spent $1.4B on share buybacks and $4.1B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 17.9×; forward P/E: 14.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.22%, paying out 43% of earnings.
Gilead Sciences, Inc. employs 17,000 people — $1.8M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Gilead Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Gilead Sciences (GILD) closed the most recent trading day at $157.48, up 2.57% from the previous session.
Why it matters — The report notes a positive single-session move in GILD shares.
Gilead Sciences said it will release its third-quarter 2026 financial results and guidance after market close on Thursday, October 29, 2026. Management will host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.
Why it matters — GILD watchers can note the date and time when the company will report quarterly results, guidance, and a business update.
Gilead Sciences expanded its oncology pipeline through a deal with Vir Biotechnology involving three novel cancer therapies and up to $1.74 billion in additional milestones.
Why it matters — The deal is relevant to GILD watchers because it adds potential oncology therapies to the company’s pipeline.
Schwab Network discussed a rotation in the AI trade and new trading opportunities. Dan Deming described Gilead Sciences as poised to continue upward price action, alongside comments on Merck and Exxon Mobil.
Why it matters — Gilead watchers may note the segment's positive characterization of the stock's price action.
Zacks Investment Research reports that users on Zacks.com have recently been watching Gilead Sciences (GILD). The article says it is worth knowing the facts that could affect the stock’s prospects.
Why it matters — The item flags increased user attention and frames relevant facts as important to those following GILD.
The 28 Wall Street analysts covering Gilead Sciences, Inc. have a median 12-month price target of $165, with estimates ranging from $126 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Gilead Sciences, Inc., 22 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Gilead Sciences, Inc. 97 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Gilead Sciences, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +4.8% from the last close, and Ticker Nerd's factor model ranks Gilead Sciences, Inc. 97 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Gilead Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GILD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $126 to $180 over the next 12 months.
Gilead Sciences, Inc. returned +36.3% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Gilead Sciences Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and life-threatening diseases.
The most recent item we track (Zacks Investment Research, 15 Oct 2026): "Gilead Sciences (GILD) Rises Higher Than Market: Key Facts". Gilead Sciences (GILD) closed the most recent trading day at $157.48, up 2.57% from the previous session.
Gilead Sciences Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and life-threatening diseases. Its current business centers on virology, oncology, and inflammation, with a particularly strong position in HIV treatment and a broader portfolio that also addresses liver disease, respiratory conditions, cardiovascular disease, and cancer. Gilead Sciences Inc. markets established therapies and newer medicines aimed at unmet medical needs, supported by ongoing research and clinical programs across multiple therapeutic areas. The company also works with partnerships and access programs that help expand the reach of its medicines in global markets. Headquartered in Foster City, California, Gilead Sciences Inc. operates as an important healthcare innovator with products and services that serve patients, clinicians, and health systems worldwide.
CEO Mr. Daniel Patrick O'Day · 17,000 employees · United States · https://www.gilead.com
